Showing 1781-1790 of 2034 results for "".
- Janssen Acquires Rights to Hemera Biosciences Investigational Gene Therapy for Late-Stage AMDhttps://modernod.com/news/janssen-acquires-rights-to-hemera-biosciences-investigational-gene-therapy-for-late-stage-amd/2478615/Janssen Pharmaceuticals announced the acquisition of rights to Hemera Biosciences’s investigational gene therapy HMR59, administered as a one-time, outpatient, intravitreal injection to help preserve vision in patients with geographic atrophy. Financial terms of the transaction with
- Samsung Bioepis Announces 1-year Results From Phase 3 Study of SB11 Proposed Lucentis Biosimilarhttps://modernod.com/news/samsung-bioepis-announces-1-year-results-from-phase-3-study-of-sb11-proposed-lucentis-biosimilar/2478526/Samsung Bioepis announced 1-year results from the phase 3 study on SB11, a proposed biosimilar to Lucentis (ranibizumab), in patients with neovascular age-related macular degeneration (AMD). This data will be presented for the first time at the American Academy of Ophthalmology (AAO) 2020 Virtual
- AGTC Reports Additional Positive Data from its Phase 1/2 Clinical Trial in Patients with X-Linked Retinitis Pigmentosahttps://modernod.com/news/agtc-reports-additional-positive-data-from-its-phase-1-2-clinical-trial-in-patients-with-x-linked-retinitis-pigmentosa/2478525/Applied Genetic Technologies Corporation (AGTC) reported positive data from its ongoing phase 1/2 clinical program in patients with X-linked retinitis pigmentosa (XLRP). Visual sensitivity, visual acuity and safety data were reported for 12-month timepoints
- Regenxbio to Receive $80 Million Milestone Payment from Novartishttps://modernod.com/news/regenxbio-to-receive-80-million-milestone-payment-from-novartis/2478475/Regenxbio announced that it will receive a milestone payment of $80 million from Novartis based upon the achievement of $1 billion in cumulative net sales of Zolgensma. Regenxbio expects to recognize this revenue in the third quarter of 2020. “Zolgensma is a transformative, one-time
- Volunteers to be Infected With Coronavirus in World’s First ‘Human Challenge’ Trialshttps://modernod.com/news/volunteers-to-be-infected-with-coronavirus-in-worlds-first-human-challenge-trials/2478437/Volunteers in London are to be infected with coronavirus early next year, in the world’s first COVID-19 “human challenge trials,” according to a Financial Times report. The project, first disclosed in the Financial Time
- STRAP Technologies Announces Device to Aid the Visually Impairedhttps://modernod.com/news/strap-technologies-announces-device-to-aid-the-visually-impaired/2478430/STRAP Technologies announced the creation of a hands-free device designed to be worn by the visually impaired to allow for more independence and mobility. STRAP is a wearable, hands-free device with an array of sensors that work by sending real-time information that detect obstacles at the
- Innovations Will Propel OCT Market to $549 Million in Revenue in 2020https://modernod.com/news/innovations-will-propel-oct-market-to-549-million-in-revenue-in-202/2478426/Recent innovations in optical coherence tomography (OCT) technology—such as systems that are combined with fundus imagers—and software advancements, including OCT angiography, are growing in popularity. At the same time promising new technologies on the horizon, such as at-home OCT devices, are g
- Blue Light Glasses Improve Sleep and Work Productivity, IU Research Showshttps://modernod.com/news/blue-light-glasses-improve-sleep-and-work-productivity-iu-research-shows/2478421/During the pandemic, the amount of screen time for many people working and learning from home as well as binge-watching TV has sharply increased. New research finds that wearing blue light glasses
- Regeneron’s Inmazeb Becomes First FDA-Approved Treatment for Ebola Virushttps://modernod.com/news/regenerons-inmazeb-becomes-first-fda-approved-treatment-for-ebola-virus/2478420/The FDA announced Wednesday that it has approved Regeneron Pharmaceuticals’ triple antibody cocktail Inmazeb (atoltivimab/maftivimab/odesivimab-ebgn) for use in adult and paediatric patients, making it the first drug cleared in the US to treat Ebola virus infection. According to the a
- Foundation Fighting Blindness To Jointly Host Online Continuing Medical Education Webinarhttps://modernod.com/news/foundation-fighting-blindness-to-jointly-host-online-continuing-medical-education-webinar/2478418/The Foundation Fighting Blindness will host an online continuing medical education (CME and COPE) course on Monday, October 19, 2020 at 12:00 p.m. eastern time. The continuing education course will review a number of topics related to care and management of patients with inherited retinal